Loading…
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for the treatment of adult patients; Trodelvy, an injection for intravenous use; and Yescarta, a suspension for intravenous infusion, is a CAR T-cell therapy for the treatment of adult patients. Further, it provides AmBisome, for the treatment of serious invasive fungal infections; and Veklury for the treatment of COVID-19. The company has collaboration agreements with Shenzhen Pregene Biopharma Co., Ltd.; Abingworth; Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company was incorporated in 1987 and is headquartered in Foster City, California.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $29.4B | $13.6B | $8.5B | $9.5B | 37.5% | 2.4% | 1672.9% |
| 2024 | $28.8B | $4.4B | $480M | $10.3B | 2.5% | 6.0% | -91.5% |
| 2023 | $27.1B | $10.5B | $5.7B | $7.4B | 24.8% | -0.6% | 23.4% |
| 2022 | $27.3B | $8.9B | $4.6B | $8.3B | 21.6% | - | - |
| 2021 | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total Revenue | - | 27,281 | 27,116 | 28,754 | 29,442 |
| Operating Revenue | - | 27,281 | 27,116 | 28,754 | 29,442 |
| Cost Of Revenue | - | 5,657 | 6,498 | 6,251 | 6,234 |
| Gross Profit | - | 21,624 | 20,618 | 22,503 | 23,208 |
| Operating Expense | - | 10,650 | 11,780 | 11,907 | 11,507 |
| Research And Development | - | 4,977 | 5,718 | 5,907 | 5,799 |
| Selling General And Administration | - | 5,673 | 6,062 | 6,000 | 5,708 |
| Total Expenses | - | 16,307 | 18,278 | 18,158 | 17,741 |
| Operating Income | - | 10,974 | 8,838 | 10,596 | 11,701 |
| Total Operating Income As Reported | - | 7,330 | 7,605 | 1,662 | 10,022 |
| EBITDA | - | 8,852 | 10,496 | 4,434 | 13,580 |
| Normalized EBITDA | - | 13,153 | 11,896 | 13,642 | 14,809 |
| EBIT | - | 6,749 | 7,803 | 1,667 | 10,820 |
| Interest Income | - | 106 | 376 | 281 | 349 |
| Interest Expense | - | 935 | 944 | 977 | 1,024 |
| Net Interest Income | - | -829 | -568 | -696 | -675 |
| Other Non Operating Income Expenses | - | -29 | -11 | -2 | -1 |
| Other Income Expense | - | -4,330 | -1,411 | -9,210 | -1,230 |
| Interest Income Non Operating | - | 106 | 376 | 281 | 349 |
| Interest Expense Non Operating | - | 935 | 944 | 977 | 1,024 |
| Net Non Operating Interest Income Expense | - | -829 | -568 | -696 | -675 |
| Pretax Income | - | 5,814 | 6,859 | 690 | 9,796 |
| Tax Provision | - | 1,248 | 1,247 | 211 | 1,286 |
| Tax Rate For Calcs | - | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | - | -923.23 | -254.80 | -2,815.78 | -161.34 |
| Net Income Continuous Operations | - | 4,566 | 5,612 | 479 | 8,510 |
| Net Income From Continuing And Discontinued Operation | - | 4,592 | 5,665 | 480 | 8,510 |
| Net Income From Continuing Operation Net Minority Interest | - | 4,592 | 5,665 | 480 | 8,510 |
| Net Income | - | 4,592 | 5,665 | 480 | 8,510 |
| Net Income Common Stockholders | - | 4,592 | 5,665 | 480 | 8,510 |
| Net Income Including Noncontrolling Interests | - | 4,566 | 5,613 | 480 | 8,510 |
| Normalized Income | - | 7,969.77 | 6,810.20 | 6,872.22 | 9,577.66 |
| Diluted NI Availto Com Stockholders | - | 4,592 | 5,665 | 480 | 8,510 |
| Basic Average Shares | - | 1,255 | 1,248 | 1,247 | 1,244 |
| Diluted Average Shares | - | 1,262 | 1,258 | 1,255 | 1,255 |
| Reconciled Depreciation | - | 2,103 | 2,693 | 2,767 | 2,760 |
| Reconciled Cost Of Revenue | - | 5,657 | 6,498 | 6,251 | 6,234 |
| Total Unusual Items | - | -4,301 | -1,400 | -9,208 | -1,229 |
| Total Unusual Items Excluding Goodwill | - | -4,301 | -1,400 | -9,208 | -1,229 |
| Minority Interests | - | 26 | 52 | 0 | 0 |
| Special Income Charges | - | -3,644 | -1,233 | -8,934 | -1,680 |
| Other Special Charges | - | 944 | 1,155 | 4,663 | 1,024 |
| Write Off | - | 2,700 | 50 | 4,180 | 590 |
| Restructuring And Mergern Acquisition | - | - | 28 | 91 | 66 |
| Gain On Sale Of Security | - | -657 | -167 | -274 | 451 |
| General And Administrative Expense | - | - | 2,790 | 2,547 | 2,186 |
| Other Gand A | - | - | 2,790 | 2,547 | 2,186 |
| Selling And Marketing Expense | - | - | 3,272 | 3,453 | 3,522 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Gilead Sciences, Inc.this co. | GILD | $160.4B | 18.85↓ discount | 7.06 | 37.5% | 12.94 |
| Amgen Inc. | AMGN | $186.5B | 24.19 | 21.54 | 89.1% | 13.73 |
| Thermo Fisher Scientific Inc. | TMO | $179.1B | 26.72 | 3.35 | 12.6% | 18.11 |
| Abbott Laboratories | ABT | $158.1B | 24.24 | 3.03 | 12.5% | 13.54 |
| Intuitive Surgical, Inc. | ISRG | $148.3B |
| - |
| - |
| - |
| - |
| - |
| - |
| 51.94 |
| 8.32 |
| 16.0% |
| 39.33 |
| Pfizer Inc. | PFE | $146.4B | 18.84 | 1.69 | 9.0% | 12.47 |
| Danaher Corporation | DHR | $132.1B | 36.55 | 2.51 | 6.9% | 21.19 |
| CVS Health Corporation | CVS | $121.0B | 68.43 | 1.61 | 2.4% | 19.52 |
| Bristol-Myers Squibb Company | BMY | $115.6B | 16.39 | 6.26 | 38.2% | 10.01 |
| Peer Median | - | 25.48 | 3.19 | 12.5% | 15.92 | |